Delving into the Latest Updates on GFRα2/3 inhibitors(Cerevel) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

Mechanism

GFRA2 antagonists(GDNF family receptor alpha 2 antagonists), GFRα3 antagonists(GDNF family receptor alpha-3 antagonists)

Therapeutic Areas

Nervous System DiseasesSkin and Musculoskeletal Diseases

Active Indication

PainPruritus

Inactive Indication-

Originator Organization

Cerevel Therapeutics LLC

Active Organization

Cerevel Therapeutics LLC

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

AbstractDepression is the most common mental illness characterized by anhedonia, avolition and loss of appetite and motivation. The majority of conventional antidepressants are monoaminergic system selective inhibitors, yet the efficacies are not sufficient. Up to 30% of depressed patients are resistant to treatment with available antidepressants, underscoring the urgent need for development of novel therapeutics to meet clinical needs. Recent years, compounds acting on the glutamate system have attracted wide attention because of their strong, rapid and sustained antidepressant effects. Among them, selective inhibitors of metabotropic glutamate receptors 2 and 3 (mGluR2/3) have shown robust antidepressant benefits with fewer side-effects in both preclinical and clinical studies. Thus, we here attempt to summarize the antidepressant effects and underlying mechanisms of these inhibitors revealed in recent years as well as analyze the potential value of mGluR2/3 selective inhibitors in the treatment of depression.

100 Deals associated with GFRα2/3 inhibitors(Cerevel)

Login to view more data